Impact of dermatological toxicities on quality of life in patients with early breast cancer exposed to adjuvant endocrine therapy: a real-world cross-sectional study - BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological adverse events)

Cancer is a disease that happens when some of the body's cells start to grow uncontrollably. Patients with breast cancer treated with anti-cancer treatment may have dermatological toxicities. These toxicities include mostly skin inflammation, hair changes, or facial flushing. These effects could be associated with negative effects on the quality of life. Therefore, it is important to reduce these effects to improve the quality of life. This will help patients to continue to take their anti-cancer treatment.

This study is an observational and transversal study. An observational study looks at how things work in everyday life. A transversal study means that data have been collected the day of the inclusion of people, and that no specific follow-up is planned in this study. This means that there are no additional visits, procedure, treatments or additional examinations compared to your usual medical care.

The aim of this study is to describe in patients with early breast cancer treated with adjuvant endocrine therapy*:

• The dermatological toxicities, and,
• Their impact on quality of life.

* Adjuvant endocrine therapy is a treatment given to patients, usually after first treatments received like surgery, to help prevent the return of hormone-sensitive cancers. It works by blocking or lowering the amount of hormones, such as estrogen, in the body. This can help to decrease or stop the growth of cancer cells linked to these hormones.